Current therapeutic approaches in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic gastrointestinal inflammatory disorder.
• Recent advancements in biologics and immunomodulators offer improved control of mucosal inflammation and ulceration, potentially altering disease progression and preventing complications.
• However, a lack of reliable markers to predict aggressive disease courses hinders the early identification of patients who would benefit most from advanced therapies.

Purpose of the Study:

• To highlight the ongoing challenges in managing IBD due to the absence of predictive markers for disease severity.
• To emphasize the importance of individualized treatment strategies based on patient and disease characteristics.
• To discuss the current therapeutic goals and available treatment modalities for IBD.

Main Methods:

• Review of current understanding of IBD etiology and pathogenesis.
• Analysis of therapeutic goals including quality of life, complication prevention, nutritional support, and disease modification.
• Examination of patient and disease characteristics (e.g., age of onset, disease location, complications, genetic markers) for treatment individualization.

Main Results:

• Current management relies on a multifaceted approach using 5-aminosalicylates, corticosteroids, immunosuppressants, antibiotics, nutritional support, and biologics.
• Individualized treatment plans are guided by patient-specific factors, influencing decisions between 'step-up' and 'top-down' therapeutic approaches.
• Treatment strategies like monotherapy versus combination therapy with biologics and immunomodulators are considered based on patient profiles.

Conclusions:

• Optimal medical management of IBD requires a personalized approach, balancing treatment efficacy with potential risks.
• Ongoing research aims to develop robust markers for predicting disease behavior and guiding therapeutic decisions.
• Future therapies may involve highly specific agents targeting identified pathways in IBD pathogenesis.